Pyruvate Dehydrogenase Complex Stimulation With Dichloroacetate May Improve Septic Cardiac Dysfunction.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research (murine model)
PubMed 41170803 · doi:10.1097/SHK.0000000000002642
What was done
Mice underwent cecal ligation and puncture (CLP) to induce sepsis and were treated with dichloroacetate (DCA) to assess pyruvate dehydrogenase (PDH) activation. Molecular assays measured PDH E1α phosphorylation and total levels. Echocardiography was conducted at 12 and 30 hours to evaluate cardiac preload, stroke volume, and contractility. Matrix-assisted laser desorption/ionization imaging mass spectrometry and metabolic profiling were used to evaluate spatial myocardial metabolite alterations.
What was found
CLP significantly increased PDH E1α phosphorylation (inactivation), which DCA treatment reversed to baseline without altering total PDH E1α levels. DCA administration at CLP improved cardiac preload and stroke volume without altering contractility at 12 hours, but significantly increased contractility at 30 hours independent of loading conditions. DCA was associated with a trend toward decreased levels of ketogenic amino acids, succinate, and palmitoyl carnitine, and mitigated CLP-induced increases in itaconate. No exact numerical data or effect sizes were reported in the abstract.
Why it matters
This study demonstrates that PDH inactivation contributes to cardiac dysfunction during sepsis and shows that metabolic reactivation with DCA can improve cardiac performance in a murine model.
Limits
The study is restricted to a murine model, limiting direct applicability to human clinical sepsis. The abstract does not report sample sizes, specific drug dosages, or exact numerical values and confidence intervals. Long-term survival and potential toxicity were not evaluated.
Cited by
- supports Dichloroacetate (DCA) activates pyruvate dehydrogenase.